`A&<i<)ci'.Ite Director‘, Lictiisirig
`
`Amgcn inc.
`one Arngtn Center Drive
`”t'.’x>us.un.l ()aks.CA 91520 I‘.-'*)*)
`Bl)5.447.1(X)O
`Direct Dial 805.44‘? 331)!)
`Faxvsos.499.93l5
`(Email itf{lnl1Cf§\‘)-"ifl1|;Cl1iL'0l'l1
`
`R,«*“‘\
`1‘
`-’-K
`
`March 13, 2000
`
`Rachid Benl-Iamza, Ph.D.Chem
`Manager, Licensing-Out
`Helsinn Healthcare SA
`PO Box 357
`6915 Pambio-Noranco
`
`Lugano Switzerland
`
`Dear Dr. BenHamza.
`
`Thank you very much for forwarding the confidential information on your SHT3
`antagonist, Palonosetron. We were very impressed with the presentation and
`thoroughness of your package. Our jobs would be much easier if all such packages were
`as complete, and easy to review. Your information caused us to analyze and explore the
`anti-emetic market more thoroughly.
`
`Unfortunately, at this point, our group is not interested in continued evaluation of
`Palonosetron. We agree the longer half-life of Palonosetron could represent a potential
`clinical advantage. However, at least in the United States, generic SHT3 antagonists
`could be available as early as 2006. This, combined with the lack of efficacy of the
`SHT3 antagonists against delayed nausea and vomiting, is the basis of our decision.
`
`Thank you again for the opportunity to review the package. We wish you continued
`success in developing Palonosetron.
`
`Sincerely.
`
`EmFlynn.Pharm.D.
`
`Associate Director
`
`Product Licensing
`Amgen
`
`cc:Linda Pullan
`
`HIGHLY CONFIDENTIAL - OUTSIDE COUNSEL EYES ONLY
`
`_HE_LSN0389420
`_
`Helsinn Healthcare Exhibit 2060
`Dr. Reddy's Laboratories, Ltd_, et al_ v. Helsinn Healthcare S_A_
`Trial PGR2016-00007
`
`Page 1 °f1